Amgen Inc. is requesting U.S. regulatory approval under fast-track guidelines for palifermin, a first-in-class investigational compound for oral mucositis. (BioWorld Today)

Just as researchers geared up to start a second pivotal trial of iseganan in ventilator-associated pneumonia (VAP), the floor fell from beneath IntraBiotics Pharmaceuticals Inc. Wednesday. (BioWorld Today)